Qingdao’s government-guided city commercial-insurance product Qindao eBao
updated and began sales on July 1, 2026, adding 10 drugs from the national first
commercial-insurance innovative-drug catalog. Total special and rare-disease
drugs covered rose to 33, including CAR-T and malignant tumor therapies. From
July 1, 2025 to May 2026 Qindao eBao registered 8.48 mln policies, paid claims
to 135,400 insureds totaling 936 mln yuan, of which specialty-drug payouts
amounted to 108 mln yuan.